达比加群治疗急性非心源性缺血性卒中
DATAS II 为 II 期前瞻性随机开放标签盲法终点试验,纳入 305 例非心源性卒中/短暂性脑缺血发作患者,随机接受达比加群或阿司匹林。结果显示两组均无症状性出血转化,无症状点状出血转化风险相似,达比加群组 7.8% 对阿司匹林组 3.5%,基线梗死体积可预测出血转化。
要点
- 急性小面积非心源性缺血性卒中/TIA 使用达比加群,出血转化风险与阿司匹林相似。
- 两组均未发生症状性出血转化,无症状点状出血转化率分别为 7.8% 和 3.5%。
- 基线梗死体积是出血转化的预测因素(OR 1.07,95%CI 1.03-1.12,P=0.0026)。
核心结论
- 达比加群在急性小面积非心源性缺血性卒中/TIA 中出血转化风险与阿司匹林相似。
研究设计与样本
- DATAS II 为 II 期前瞻性随机开放标签盲法终点试验,共纳入 305 例患者。
- 患者为非心源性卒中/TIA,NIHSS 评分≤9,梗死体积≤25 mL,随机接受达比加群或阿司匹林。
- 随机化前及第 30 天进行磁共振成像,影像终点由对治疗分组不知情的中心阅片者判定。
主要发现
- 共 305 例患者随机,平均年龄 66.59±13.21 岁,症状发作后平均 42.00±17.31 小时随机化。
- 21% 为 TIA,79% 为缺血性卒中;NIHSS 中位数 1(0-2),平均梗死体积 3.2±6.5 mL。
- 无症状点状出血转化在达比加群组为 11/142(7.8%),阿司匹林组为 5/142(3.5%),相对风险 2.301(95%CI 0.778-6.802)。
- 基线梗死体积预测出血转化(OR 1.07,95%CI 1.03-1.12,P=0.0026)。
- 第 30 天新发隐匿性梗死达比加群组 9/142(6.3%),阿司匹林组 14/142(9.8%),相对风险 0.62(95%CI 0.26-1.48)。
关键数值与推荐
- 主要终点为随机化后 37 天内症状性出血转化,两组均未发生。
临床怎么用
- 对于急性小面积非心源性缺血性卒中/TIA,达比加群可作为抗栓选择之一,出血转化风险与阿司匹林相近。
- 基线梗死体积较大的患者应关注出血转化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Patients with transient ischemic attack (TIA) and minor ischemic stroke are at risk for early recurrent cerebral ischemia. Anticoagulants are associated with reduced recurrence but also increased hemorrhagic transformation (HT). The safety of the novel oral anticoagulant dabigatran in acute stroke has not been evaluated. Methods- DATAS II (Dabigatran Treatment of Acute Stroke II) was a phase II prospective, randomized open label, blinded end point trial. Patients with noncardioembolic stroke/transient ischemic attack (National Institutes of Health Stroke Scale score, ≤9; infarct volume, ≤25 mL) were randomized to dabigatran or aspirin. Magnetic resonance imaging was performed before randomization and repeated at day 30. Imaging end points were ascertained centrally by readers blinded to treatment. The primary end point was symptomatic HT within 37 days of randomization. Results- A total of 305 patients, mean age 66.59±13.21 years, were randomized to dabigatran or aspirin a mean of 42.00±17.31 hours after symptom onset. The qualifying event was a transient ischemic attack in 21%, and ischemic stroke in 79% of patients. Median National Institutes of Health Stroke Scale (interquartile range) was 1 (0-2), and mean infarct volume 3.2±6.5 mL. No symptomatic HT occurred. Asymptomatic petechial HT developed in 11/142 (7.8%) of dabigatran-assigned patients and 5/142 (3.5%) of aspirin-assigned patients (relative risk, 2.301 [95% CI, 0.778-6.802]). Baseline infarct volume predicted incident HT (odds ratio, 1.07 [95% CI, 1.03-1.12]; P=0.0026). Incident covert infarcts on day 30 imaging occurred in 9/142 (6.3%) of dabigatran-assigned and 14/142 (9.8%) of aspirin-assigned patients (relative risk, 0.62 [95% CI, 0.26, 1.48]). Conclusions- Dabigatran was associated with a risk of HT similar to aspirin in acute minor noncardioembolic ischemic stroke/transient ischemic attack. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT02295826.
引用
- Butcher KS, Ng K, Sheridan P, et al. Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke. Stroke. 2020. PMID: 32098609. doi:10.1161/STROKEAHA.119.027569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。